1-20 of 185
Funda Meric-Bernstam
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Abstract CT243: Phase 2 study of Ivonescimab in patients with cutaneous squamous cell carcinoma

Free
Neal Akhave, Ashley Holder, Michael Davies, Omar Pacha, Roi Weiser, Funda Meric-Bernstam, Aung Naing
Journal: Cancer Research
Cancer Res (2025) 85 (8_Supplement_2): CT243.
https://doi.org/10.1158/1538-7445.AM2025-CT243
Published: 25 April 2025
View articletitled, Abstract CT243: Phase 2 study of Ivonescimab in patients with cutaneous squamous cell carcinoma
Journal Articles

Abstract CT046: Clinical and translational study of the TGF-β monoclonal antibody SAR439459 in combination with the PD-1 inhibitor cemiplimab for patients (pts) with advanced solid tumors: Results from the phase 1b TACTIC trial

Free
Carlos Torrado, Katarzyna Tomczak, Ecaterina E. Dumbrava, Baohua Sun, Natalie Ngoi, Claudio Arrechedera, Edwin R. Parra, Jordi Rodon Anhert, Sarina A. Piha-Paul, Apostolia M. Tsimberidou, Siqing Fu, Aung Naing, Paula R. Pohlmann, David S. Hong, Funda Meric-Bernstam, Pavlos Msaouel, Cara L. Haymaker, Timothy A. Yap
Journal: Cancer Research
Cancer Res (2025) 85 (8_Supplement_2): CT046.
https://doi.org/10.1158/1538-7445.AM2025-CT046
Published: 25 April 2025
View articletitled, Abstract CT046: Clinical and translational study of the TGF-β monoclonal antibody SAR439459 in combination with the PD-1 inhibitor cemiplimab for patients (pts) with advanced solid tumors: Results from the phase 1b TACTIC trial
Journal Articles

Abstract CT226: Sunitinib (S) in patients (pts) with solid tumors with FGFR2 alterations: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) Study

Free
Gordan Srkalovic, Michael Rothe, Pam K. Mangat, Elizabeth Garrett-Mayer, Kathryn F. Mileham, Bamidele Adesunloye, Natalia Colocci, M. Dwight Chen, Funda Meric-Bernstam, Evan Pisick, Alissa S. Marr, Amin Benyounes, Olatunji B. Alese, Abigail Gregory, Dominique C. Hinshaw, Gina N. Grantham, Susan Halabi, Richard L. Schilsky
Journal: Cancer Research
Cancer Res (2025) 85 (8_Supplement_2): CT226.
https://doi.org/10.1158/1538-7445.AM2025-CT226
Published: 25 April 2025
View articletitled, Abstract CT226: Sunitinib (S) in patients (pts) with solid tumors with FGFR2 alterations: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) Study
Journal Articles

Abstract CT200: Safety and efficacy of HLA-G-targeted CAR T cells (IVS-3001) in patients with advanced HLA-G-positive solid tumors: Clinical trial in progress

Free
Samer A. Srour, Nizar Tannir, Amir Jazaeri, Matthew T. Campbell, Yago Nieto, Cara Haymaker, Ying Yuan, Israa Salih, Yali Yang, Valerie Doppler, Julie Garibal, Marie Escande, Melissa Yang, Jake Kushner, Jake Kushner, Jane Koo, Serdar A. Gurses, David S. Hong, Siqing Fu, Funda Meric-Bernstam, Aung Naing
Journal: Cancer Research
Cancer Res (2025) 85 (8_Supplement_2): CT200.
https://doi.org/10.1158/1538-7445.AM2025-CT200
Published: 25 April 2025
View articletitled, Abstract CT200: Safety and efficacy of HLA-G-targeted CAR T cells (IVS-3001) in patients with advanced HLA-G-positive solid tumors: Clinical trial in progress
Journal Articles

Abstract CT235: REPLOT Trial: Phase II study of repotrectinib with or without fulvestrant in patients with HR+ HER2- metastatic invasive lobular carcinoma previously treated with endocrine therapy and CDK4/6 inhibition

Free
Jason A. Mouabbi, Amy Hammell, Shailaja Suryawanshi, Lavinia Middleton, Roland Bassett, Toni Zaayman, Livia Geoffrey, Funda Meric-Bernstam
Journal: Cancer Research
Cancer Res (2025) 85 (8_Supplement_2): CT235.
https://doi.org/10.1158/1538-7445.AM2025-CT235
Published: 25 April 2025
View articletitled, Abstract CT235: REPLOT Trial: Phase II study of repotrectinib with or without fulvestrant in patients with HR+ HER2- metastatic invasive lobular carcinoma previously treated with endocrine therapy and CDK4/6 inhibition
Journal Articles

Abstract CT249: An open-label, multicenter, phase 2 study of trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2-expressing solid tumors: DESTINY-PanTumor02 (DP-02) Part 2

Free
Funda Meric-Bernstam, Jung-Yun Lee, Vicky Makker, Ana Oaknin, Chiedozie Anoka, Lindsey Jung, Soham Puvvada, João Simões, Do Youn Oh
Journal: Cancer Research
Cancer Res (2025) 85 (8_Supplement_2): CT249.
https://doi.org/10.1158/1538-7445.AM2025-CT249
Published: 25 April 2025
View articletitled, Abstract CT249: An open-label, multicenter, phase 2 study of trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2-expressing solid tumors: DESTINY-PanTumor02 (DP-02) Part 2
Journal Articles

Abstract 3254: Cell-free DNA molecular response predicts clinical efficacy in HGSOC patients treated with azenosertib

Free
Jinkil Jeong, Jianhui Ma, Mona Abed, Heekyung Chung, Doris Kim, Nandini Molden, Divya Rajendran, Chang Shim, Danielle D. Jandial, Mark R. Lackner, Fiona Simpkins, Funda Meric-Bernstam, Leslie M. Randall, Olivier Harismendy
Journal: Cancer Research
Cancer Res (2025) 85 (8_Supplement_1): 3254.
https://doi.org/10.1158/1538-7445.AM2025-3254
Published: 21 April 2025
View articletitled, Abstract 3254: Cell-free DNA molecular response predicts clinical efficacy in HGSOC patients treated with azenosertib
Journal Articles

Abstract 809: Food choices of patients with advanced cancer at start of early-phase combination trials with immune checkpoint blockade

Free
Goldy C. George, Hangil Lee, Sarina A. Piha-Paul, Ecaterina Dumbrava, Apostolia Tsimberidou, Siqing Fu, Grace Appleton, Laila Noor, Jordi Rodon, Timothy A. Yap, Funda Meric-Bernstam, David S. Hong
Journal: Cancer Research
Cancer Res (2025) 85 (8_Supplement_1): 809.
https://doi.org/10.1158/1538-7445.AM2025-809
Published: 21 April 2025
View articletitled, Abstract 809: Food choices of patients with advanced cancer at start of early-phase combination trials with immune checkpoint blockade
Journal Articles

Abstract 1711: Genomic and transcriptomic mediators of resistance to antibody-drug conjugates (ADCs) in metastatic breast cancer (MBC): A comprehensive multi-center study

Free
Samer Alkassis, Marla Lipsyc-Sharf, Catherine Hegarty-Traverso, Jacob Mercer, Binyam Yilma, Stamatina Fragkogianni, Yuan Yuan, Funda Meric-Bernstam, Hope Rugo, Joyce O’Shaughnessy, Mothaffar Rimawi, Rachel Schiff, David Elashoff, John Glaspy, Martina McDermott, Amy Cummings, Calvin Chao, Aditya Bardia
Journal: Cancer Research
Cancer Res (2025) 85 (8_Supplement_1): 1711.
https://doi.org/10.1158/1538-7445.AM2025-1711
Published: 21 April 2025
View articletitled, Abstract 1711: Genomic and transcriptomic mediators of resistance to antibody-drug conjugates (ADCs) in metastatic breast cancer (MBC): A comprehensive multi-center study
Journal Articles

Abstract 739: Patient-derived xenografts allow deconvolution and prediction of chemotherapy responses

Free
Jonathan T. Lei, Lacey E. Dobrolecki, Chen Huang, Ramakrishnan R. Srinivasan, Suhas V. Vasaikar, Alaina N. Lewis, Christina Sallas, Na Zhao, Jin Cao, John D. Landua, Chang I. Moon, Yuxing Liao, Susan G. Hilsenbeck, C K. Osborne, Mothaffar F. Rimawi, Matthew J. Ellis, Varduhi Petrosyan, Bo Wen, Kai Li, Alexander B. Saltzman, Antrix Jain, Anna Malovannaya, Gerburg M. Wulf, Elisabetta Marangoni, Shunqiang Li, Daniel C. Kraushaar, Tao Wang, Senthil Damodaran, Xiaofeng Zheng, Funda Meric-Bernstam, Gloria V. Echeverria, Meenakshi Anurag, Xi Chen, Bryan E. Welm, Alana L. Welm, Bing Zhang, Michael T. Lewis
Journal: Cancer Research
Cancer Res (2025) 85 (8_Supplement_1): 739.
https://doi.org/10.1158/1538-7445.AM2025-739
Published: 21 April 2025
View articletitled, Abstract 739: Patient-derived xenografts allow deconvolution and prediction of chemotherapy responses
Journal Articles

Abstract 5952: Modulating treatment outcomes of patients with solid tumors in immunotherapy trials: a drug interaction analysis from a phase I unit

Free
Camila Braganca Xavier, Clark Andersen, JoAnn T. Lim, Julian H. Slade, Stacie A. Bean, Lei Kang, Hung Le, Apostolia Tsimberidou, Aung Naing, David Hong, Ecaterina Dumbrava, Jordi Rodon, Paula Pohlmann, Sarina Piha-Paul, Stephane Champiat, Timothy A. Yap, Tin-Yun Tang, Funda Meric-Bernstam, Siqing Fu
Journal: Cancer Research
Cancer Res (2025) 85 (8_Supplement_1): 5952.
https://doi.org/10.1158/1538-7445.AM2025-5952
Published: 21 April 2025
View articletitled, Abstract 5952: Modulating treatment outcomes of patients with solid tumors in immunotherapy trials: a drug interaction analysis from a phase I unit
Journal Articles

Abstract 1121: Pan-cancer prevalence of unusual MTAP alterations: data from the AACR GENIE database

Free
Mohamed A. Gouda, Camila B. Xavier, Carlos Torrado, Pooja A. Shah, Kunal Rai, Natalie Vokes, Omar Alhalabi, Mark T. Bedford, Jianjun Gao, Nazanin K. Majd, Jenny Li, Milind Javle, Funda Meric-Bernstam, Jordi Rodon
Journal: Cancer Research
Cancer Res (2025) 85 (8_Supplement_1): 1121.
https://doi.org/10.1158/1538-7445.AM2025-1121
Published: 21 April 2025
View articletitled, Abstract 1121: Pan-cancer prevalence of unusual MTAP alterations: data from the AACR GENIE database
Journal Articles

Abstract 4209: Targeting RNase H2: a dual mechanism strategy to elevate replication stress, DNA damage, and antitumor immunity in triple-negative breast cancer

Free
Thai Quynh Anh Nguyen, Daniel J. McGrail, Hui Dai, Aysegul Cifci, Yong Du, Funda Meric-Bernstam, Shiaw-Yih Lin
Journal: Cancer Research
Cancer Res (2025) 85 (8_Supplement_1): 4209.
https://doi.org/10.1158/1538-7445.AM2025-4209
Published: 21 April 2025
View articletitled, Abstract 4209: Targeting RNase H2: a dual mechanism strategy to elevate replication stress, DNA damage, and antitumor immunity in triple-negative breast cancer
Journal Articles

A Pan-Cancer Patient-Derived Xenograft Histology Image Repository with Genomic and Pathologic Annotations Enables Deep Learning Analysis

Open Access
Brian S. White, Xing Yi Woo, Soner Koc, Todd Sheridan, Steven B. Neuhauser, Shidan Wang, Yvonne A. Evrard, Li Chen, Ali Foroughi pour, John D. Landua, R. Jay Mashl, Sherri R. Davies, Bingliang Fang, Maria Gabriela Raso, Kurt W. Evans, Matthew H. Bailey, Yeqing Chen, Min Xiao, Jill C. Rubinstein, Brian J. Sanderson, Michael W. Lloyd, Sergii Domanskyi, Lacey E. Dobrolecki, Maihi Fujita, Junya Fujimoto, Guanghua Xiao, Ryan C. Fields, Jacqueline L. Mudd, Xiaowei Xu, Melinda G. Hollingshead, Shahanawaz Jiwani, Saul Acevedo, PDXNet Consortium, Brandi N. Davis-Dusenbery, Peter N. Robinson, Jeffrey A. Moscow, James H. Doroshow, Nicholas Mitsiades, Salma Kaochar, Chong-xian Pan, Luis G. Carvajal-Carmona, Alana L. Welm, Bryan E. Welm, Ramaswamy Govindan, Shunqiang Li, Michael A. Davies, Jack A. Roth, Funda Meric-Bernstam, Yang Xie, Meenhard Herlyn, Li Ding, Michael T. Lewis, Carol J. Bult, Dennis A. Dean, II, Jeffrey H. Chuang
Journal: Cancer Research
Cancer Res (2024) 84 (13): 2060–2072.
https://doi.org/10.1158/0008-5472.CAN-23-1349
Published: 02 July 2024
View articletitled, A Pan-Cancer Patient-Derived Xenograft Histology Image Repository with Genomic and Pathologic Annotations Enables Deep Learning Analysis
Open the PDF for A Pan-Cancer Patient-Derived Xenograft Histology Image Repository with Genomic and Pathologic Annotations Enables Deep Learning Analysis in another window
Includes: Supplementary data
Journal Articles

Abstract RF01-07: The efficacy and safety of tinengotinib in patients with advanced or metastatic HR+/HER2- breast cancer or TNBC

Free
Piha-Paul Sarina, Binghe Xu, Ying Fan, Yuan Yuan, Sayeh Lavasani, Joanne Mortimer, Sanjay Goel, Apostolia Tsimberidou, Nuhad Ibrahim, Sausan Abouharb, Carlos Barcenas, Adaeze lheme, Daniel Karp, Jordi Rodon Ahnert, Ecaterina Dumbrava, Jean Fan, Peng Peng, Caixia Sun, Hui Wang, Katie Hennessy, Ximei Fu, Ruolan Xu, Shumao Ni, Frank Wu, Funda Meric-Bernstam
Journal: Cancer Research
Cancer Res (2024) 84 (9_Supplement): RF01-07.
https://doi.org/10.1158/1538-7445.SABCS23-RF01-07
Published: 02 May 2024
View articletitled, Abstract RF01-07: The efficacy and safety of tinengotinib in patients with advanced or metastatic HR+/HER2- breast cancer or TNBC
Journal Articles

Abstract PO5-05-03: Phase 1/2 Dose Expansion Study Evaluating First-In-Class eIF4A Inhibitor Zotatifin in Patients with ER+ Metastatic Breast Cancer

Free
Ezra Y. Rosen, Manish Sharma, David Berz, Jennifer Caswell-Jin, Georgina Fulgar, Mark Densel, Gary Chiang, Samuel Sperry, Douglas Warner, Funda Meric-Bernstam
Journal: Cancer Research
Cancer Res (2024) 84 (9_Supplement): PO5-05-03.
https://doi.org/10.1158/1538-7445.SABCS23-PO5-05-03
Published: 02 May 2024
View articletitled, Abstract PO5-05-03: Phase 1/2 Dose Expansion Study Evaluating First-In-Class eIF4A Inhibitor Zotatifin in Patients with ER+ Metastatic Breast Cancer
Journal Articles

Abstract PO3-19-10: Phase 1b study of EZH1/2 inhibitor valemetostat in combination with trastuzumab deruxtecan in subjects with HER2 low/ultra-low/null metastatic breast cancer

Free
Senthil Damodaran, Toshiaki Iwase, Angela Marx, Jie Willey, Funda Meric-Bernstam, Debu Tripathy, Carlos Barcenas, Jangsoon lee, Naoto Ueno
Journal: Cancer Research
Cancer Res (2024) 84 (9_Supplement): PO3-19-10.
https://doi.org/10.1158/1538-7445.SABCS23-PO3-19-10
Published: 02 May 2024
View articletitled, Abstract PO3-19-10: Phase 1b study of EZH1/2 inhibitor valemetostat in combination with trastuzumab deruxtecan in subjects with HER2 low/ultra-low/null metastatic breast cancer
Journal Articles

Abstract PO3-15-03: Abemaciclib is effective in palbociclib resistant estrogen receptor positive breast cancers

Free
Juliana Navarro-Yepes, Nicole Kettner, Xiayu Rao, Tuyen Bui, Cassandra Bishop, Hannah Wingate, Akshara Singareeka Raghavendra, Yan Wang, Jing Wang, Aysegul Sahin, Funda Meric-Bernstam, Kelly Hunt, Senthil Damodaran, Debu Tripathy, Khandan Keyomarsi
Journal: Cancer Research
Cancer Res (2024) 84 (9_Supplement): PO3-15-03.
https://doi.org/10.1158/1538-7445.SABCS23-PO3-15-03
Published: 02 May 2024
View articletitled, Abstract PO3-15-03: Abemaciclib is effective in palbociclib resistant estrogen receptor positive breast cancers
Journal Articles

Abstract PS09-03: Neoadjuvant zanidatamab for stage I node negative HER2 positive breast cancer

Free
Vicente Valero, Jason Mouabbi, Heather Alonzo, Paula Pohlmann, Adaeze Lheme, Amy Hassan, Rashmi Murthy, Xuelin Huang, Wei Qiao, Miral Patel, Gaiane Rauch, Cristina Checka, W. Fraser Symmans, Kelly Hunt, Debu Tripathy, Funda Meric-Bernstam
Journal: Cancer Research
Cancer Res (2024) 84 (9_Supplement): PS09-03.
https://doi.org/10.1158/1538-7445.SABCS23-PS09-03
Published: 02 May 2024
View articletitled, Abstract PS09-03: Neoadjuvant zanidatamab for stage I node negative HER2 positive breast cancer
Journal Articles

Abstract CT077: An open-label phase 1 study to investigate SGN-CEACAM5C in adults with advanced solid tumors (SGNCEA5C-001, Trial in Progress)

Free
Funda Meric-Bernstam, Cesar A. Perez, Nehal Lakhani, Meredith Pelster, Justin Call, Suzanne McGoldrick, Tianhua Wang, Brigitte Demers, Amita Patnaik
Journal: Cancer Research
Cancer Res (2024) 84 (7_Supplement): CT077.
https://doi.org/10.1158/1538-7445.AM2024-CT077
Published: 05 April 2024
View articletitled, Abstract CT077: An open-label phase 1 study to investigate SGN-CEACAM5C in adults with advanced solid tumors (SGNCEA5C-001, Trial in Progress)